Programme

Panos is Visiting Professor at the University of Basel, Switzerland and has previously been Harkness Fellow in Health Care Policy at Harvard Medical School. He is an Economist by training, currently coordinates the Programme in International Health Policy and teaches Health Economics, Pharmaceutical Economics and Policy, Health Care Financing, and Health Systems Performance Measurement. Panos leads the activities of MTRG, which is a research unit comprising 11 researchers within LSE Health and concentrates on interdisciplinary and comparative policy research on medical technologies. MTRG administers the Programme on Pharmaceutical Policy Issues, the Programme on Medical Devices, conducts research in the European Medicines Information Network, the network for the study of rare diseases, a major research initiative on Health Technology Assessment and is a member of the European Health Technology Institute for Socio-Economic Research. Panos was an advisor in the following organizations: the European Commission, the European Parliament, the World Bank, the World Health Organization, the American Association for Retired Persons, and Ministries of Health.

Michael is Executive Vice President, Established Pharmaceuticals since April 2010, focusing on expanding the global market for Abbott’s branded generics portfolio. Most recently, Michael was SVP, Diagnostics, heading Abbott’s global core laboratory diagnostics business. Michael joined Abbott in 1986 as part of Abbott’s manufacturing professional development program. He served in a variety of management roles including VP and GM, Hematology, in Abbott’s Diagnostics business; VP, Global Engineering Services; DVP Pharmaceutical Operations; and DVP of Corporate Quality Operations. He earned a bachelor’s degree in business administration from the University of Wisconsin-Whitewater and a master’s degree in business administration from Northwestern University.

<p> Born in Moscow, Russia on 27 August 1979.Graduated from the State University “Higher School of Economics”, Diploma in Economy and Business Administration.Since 1995 in Healthcare and Pharmaceutics.R-Pharm Founder. President of All-Russia Business Association “Delovaya Rossiya” (“Business Russia”), actively participating in the improvement of investment climate in the Russian Federation and the establishment of the regional investment standard.Member of the Economic Council under the President of the Russian Federation.Member of the Presidential Council for Priority National Projects and Demographic Policy.Member of the Expert Council under the Government of the Russian Federation. Member of the Public Chamber of the Russian Federation, Head of Commission on Investment Climate.Representative (public ombudsman) of the Commissioner of the Presidential Council on the protection of the rights of entrepreneurs on issues related to the protection of the rights of foreign investors.Board-member and Co-chairman of Committee of the Russian Union of Industrialists and Entrepreneurs on pharmaceutical and medical industry.Co-Chairman of the National Rating CommitteeMember of the Public Council under the Ministry of Industry and Trade of the Russian Federation (pharmaceutical, medical equipment and technologies).Member of the Supervisory Board of the Autonomous Nonprofit Organization "Agency for Strategic Initiatives". </p>

Mark Kurtser is the founder of the Mother and Child Group of Companies, Chairman of the Group’s Board of Directors, a correspondent member of the Russian Academy of Sciences, a doctor of medicine and a professor. He began his career at the Department of Obstetrics and Gynaecology of the Pirogov Second Moscow State Medical Institute, where he worked his way up from assistant to associate professor of the department. From 1994 to 2012, Kurtser was head of the Family Planning and Reproduction Centre of the Moscow Healthcare Department, the largest obstetrics and gynaecology institution in Moscow. In 2011, he defended his doctoral dissertation. From 2003 to 2013, he was the chief obstetrician and gynaecologist within the Moscow Healthcare Department. The Mother and Child Welfare programme was prepared with his involvement as part of the Municipal Targeted Programme for Healthcare Development for 2006–2007 and guidelines were developed for health and demographic indicators. The level of maternal and perinatal mortality declined in the city. Kurtser is the author of 45 scientific works, more than eleven textbooks and practical guidelines in obstetrics and gynaecology. PhD dissertations are held under his guidance. Kurtser is actively involved in holding conventions and symposiums and also lectures for practicing physicians and residents. He introduces innovative medical technologies to the work of obstetrics and gynaecology in-patient clinics. Kurtser remains actively involved in the activities of the Mother and Child Group both as an executive and as regular medical practitioner.

Simon Matskeplishvili, MD, PhD, FESC, FACC, is a Professor of Cardiology and a Chief Scientific and Clinical Researcher at the Bakoulev Scientific Center for Cardiovascular Surgery in Moscow and an adjunct professor of life sciences at the Moscow Institute of Physics and Technology. He also serves as a member of the Education, Certification and Accreditation, European Communities Committees of the European Association of Cardiovascular Imaging. He graduated with honors from the Moscow Medical Academy in 1994 and had his postgraduate training and fellowship in cardiology at the Clinico-Diagnostic Department of the Bakoulev Center. In 1997-1998 he received a degree of the International Master in Cardiology from the Institute of Clinical Physiology of the National Research Council of Italy in Pisa. Simon Matskeplishvili is a Fellow of the European Society of Cardiology and a Fellow of the American College of Cardiology. He has received numerous honours and awards, both in Russia and internationally, including the European Cardiology award in 2001. He is a founder and a Chairman of the echocardiography section of the Russian society of cardiology. In 2007 he became a full professor of cardiology. For the development of new non-invasive method of intracardiac blood flow evaluation in 2012 he was awarded a State Prize of the Government of Russian Federation in science and technology. In 2013 he was a captain of the Russian team to win an ESC Cardiology Quiz “Primus inter pares” at the European Congress of Cardiology in Amsterdam. In 2012 Professor Simon Matskeplishvili had organized and implemented the Educational Program for cardiologists and internal medicine physicians in Moscow. He also conducts an English-language elective course “Amazing Cardiology” in cardiology, cardiac surgery and cardiovascular imaging at the Faculty of Medicine of the Lomonosov Moscow State University. The Board of the European Society of Cardiology has appointed Simon Matskeplishvili as the Coordinator of the Congress Programme Committee of the European Society of Cardiology Congress 2015-2016.

Mark Mallon is responsible for the growth and performance of AstraZeneca’s International region, which predominantly includes AstraZeneca’s commercial businesses in Asia Pacific, Russia, Latin America, the Middle East and Africa. Most recently, Mark served as Regional Vice President for Asia Pacific where he was accountable for the growth and performance of the AstraZeneca business in 14 markets. While in this role Mark has also served as President of AstraZeneca China, responsible for the company’s overall operations in China and Hong Kong. Previously, Mark led the marketing, sales and commercial operations for AstraZeneca K. K. (Japan). Since joining AstraZeneca in 1994, Mark has held a number of additional leadership roles, Including Marketing Company President of the AstraZeneca Italian subsidiary company and Vice President of Marketing and Sales Operations of AstraZeneca’s US business. While in the US, Mark also was a Board Member for the Christiana Care Network, one of the largest healthcare networks on the East Coast. Mark received a Bachelor of Science degree in Chemical Engineering from the University of Pennsylvania and an MBA in Marketing and Finance from the Wharton School of Business. He is based in Shanghai.

He was born in 1973 Jaipur, India, has left “Birla Public School”, Pilani. He came to Russia in 1972, after the termination of a language course entered Irkutsk State Medical University. He also has the higher economic education of Far East State University. In 1997 he built up JSC “Pharmasyntez” and worked as the General Director. He is Chairman of board of directors since 2004. During work three pharmaceutical factories were built: two of them are in Irkutsk (producing solid medical products), one - in Ussuriisk, Primorski Krai (manufacturing infusion solutions on Swiss technology “Bottle Pack”).

Veronika Skvortsova was born in Moscow on November 1, 1960. She graduated from the 2nd Pirogov Moscow State Medical Institute in 1983 and completed a Postgraduate Clinical Residency Programme and an Advanced Postgraduate Programme specializing in neuropathology. In 1994, she qualified as a higher category neurologist. After graduating, she worked for the 2nd Moscow State Medical Institute (the Russian State Medical University since 1991) for 25 years. Veronika Skvortsova became head of one of Russia’s first neurology emergency services at Moscow’s 1st municipal hospital established on the basis of the neurology clinic of the 2nd Moscow State Medical Institute in 1989. In 1989–1995, she served as assistant and, in 1995–1997, as assistant professor at the Neuropathology Department of the Russian State Medical University. She became Head of the Fundamental and Clinical Neurology and Neurosurgery Department in 1997. Veronika Skvortsova was appointed Director of the Russian Stroke Research Institute in 2005. She was Deputy Minister of Healthcare and Social Development from 2008 to 2012. Veronika Skvortsova was appointed Minister of Healthcare by Presidential Executive Order No. 650 of May 21, 2012. She is vice-president and co-founder of the National Stroke Association, director of the World Stroke Organization and secretary general of the European Stroke Council. She is a Doctor of Medicine, Professor, and Corresponding Member of the Russian Academy of Medical Sciences. Veronika Skvortsova is an Honored Scientist of the Russian Federation. She has been awarded an Order of Honour and won the Pirogov Prize and Moscow Government Prize in Medicine. She is the author of more than 400 research papers and holds seven patents for her inventions.

Dr. Paul Stoffels is Worldwide Chairman Pharmaceuticals and Chief Research Officer Johnson & Johnson, Member of Executive Committee, Johnson & Johnson. He works with stakeholders across Johnson & Johnson to set the enterprise-wide innovation agenda. Dr. Stoffels is a member of the Johnson & Johnson Executive Committee and Management Committee. Dr. Stoffels as the Worldwide Chairman of Janssen, Pharmaceutical Companies of Johnson & Johnson, has responsibility for expansion of the company’s therapeutic pipeline through global R&D and strategic partnerships, licensing and acquisitions. Dr. Stoffels chairs the Worldwide Research & Development Council, with a mandate to maximize R&D productivity, leverage R&D capabilities, share best practices and foster R&D talent across the organization. He also provides oversight to the Johnson & Johnson Development Corporation (JJDC) and the Johnson & Johnson innovation centers, with the goal of catalyzing innovative science and technology. Dr. Stoffels studied Medicine at the University of Diepenbeek and the University of Antwerp in Belgium and Infectious Diseases and Tropical Medicine at the Institute of Tropical Medicine in Antwerp.

Patrick is responsible for Ernst & Young’s strategy, thought leadership and branding, learning and network development to best serve our clients in the Life Sciences Industry in Europe and globally. Patrick also serves as the Global Client Service Partner or as senior advisory partner on a number of European Pharmaceutical clients. He has served on various management and leadership positions at Ernst & Young at global and EMEIA levels. He has had a long career in auditing and consulting, starting in 1979 in Paris and moving to Brussels in 1989 to lead Ernst & Young EU Policy and Regulation team providing strategic advisory services to Fortune 500 companies in the industrial and financial sectors. He joined our Change Management practice in Paris in 1995 while setting up the French practice’s marketing and communications department and later moved to London as Global Vice-Chair for business development. Patrick is a frequent speaker at Life Sciences and Healthcare related conferences and has contributed numerous articles on the industry in the trade and general press. Patrick Flochel has a Master’s degree from ESCP in Paris.

Education: 1974 – Military Institute of Foreign Languages. 1991 – Russian State University for the Humanities. Professional activities: Mr. Shipkov began his career in law enforcement. From 1998 to 2000, he was a board member of the State Customs Committee of the Russian Fed-eration. In 1999, he was appointed director of the Personnel Department and a board member of the State Customs Committee and then worked in the State Duma administrative office. From 2000 to 2004, he served as director of pharmaceutical inspections at the Ministry of Healthcare. In 2004, he was appointed deputy director of the Federal Service for Intellectual Property, Patents and Trademarks (Rospatent). He also took part in the work of a medicine licensing commission of the Federal Service for the Supervision of Public Health and Social Development. Since 2007, he has been the executive director of AIPM.

David Epstein is Division Head, Novartis Pharmaceuticals. Prior to this appointment, David served as President, Novartis Oncology, with activities ranging from Discovery & Development to Marketing & Sales. He was also responsible for staring up and leading Novartis Molecular Diagnostics. Previously, David served as CEO, Novartis Specialty Medicines, overseeing the global Ophthalmics and Transplantation & Immunology Business Units. He also served as Chief Operating Officer of Novartis Pharmaceuticals Corporation in the U.S. and has held several positions in marketing and general management. David began his career with the company in 1989 at Sandoz Ltd. David holds a Bachelor degree in Pharmacy with high honors from Rutgers University College of Pharmacy and an MBA in Finance and Marketing from the Columbia University Graduate School of Business.